Strontium ranelate analgesia in arthritis models is associated to decreased cytokine release and opioid-dependent mechanisms.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]

PubMedID: 26245235

de Melo Nunes R, Martins MR, da Silva Junior FS, de Melo Leite AC, Girão VC, de Queiroz Cunha F, Marinho AL, Pinto AC, Rocha FA. Strontium ranelate analgesia in arthritis models is associated to decreased cytokine release and opioid-dependent mechanisms. Inflamm Res. 2015;.
OBJECTIVE
We investigated the anti-inflammatory activity of strontium ranelate (SR) in arthritis models.

MATERIALS AND METHODS
Rats received 1 mg zymosan (Zy) or saline intra-articularly. Other groups were subjected to anterior cruciate ligament transection in the right knee, as an osteoarthritis (OA) model, or a sham procedure. Joint pain was assessed using the articular incapacitation and paw-pressure tests. Cell influx and cytokines were measured in joint exudates.

TREATMENT
Groups received either SR (30-300 mg/kg per os) or saline.

RESULTS
SR dose-dependently and significantly inhibited joint pain in both Zy and OA models, while not altering cell influx. Naloxone administration significantly reversed SR analgesia. SR significantly reduced levels of Interleukin-1ß and tumor necrosis factor-a in Zy arthritis, whereas those of cytokine-induced neutrophil chemoattractant (CINC)-1 were not altered.

CONCLUSIONS
SR provides analgesia in arthritis that is associated to inhibition of the release of inflammatory cytokines into inflamed joints. This effect is abrogated by administration of the opioid antagonist naloxone.